MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-03-2022
SeaSpine Holdings Corporation Total Assets 2011-2026 | SPNE
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets SeaSpine Holdings Corporation
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 377 M | 214 M | 142 M | 172 M | 134 M | 147 M | 176 M | 140 M | 153 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 377 M | 134 M | 184 M |
Quarterly Total Assets SeaSpine Holdings Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 374 M | - | 380 M | 377 M | 390 M | 400 M | 230 M | 214 M | 214 M | 214 M | 214 M | 142 M | 142 M | 142 M | 142 M | 172 M | 172 M | 172 M | 172 M | 134 M | 134 M | 134 M | 134 M | 147 M | 147 M | 147 M | 147 M | 176 M | 176 M | 176 M | 176 M | 140 M | 140 M | 140 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 400 M | 134 M | 197 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | USA |
 |
Tactile Systems Technology
TCMD
|
274 M | $ 26.39 | -1.46 % | $ 604 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | USA |
 |
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | USA |
 |
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | USA |
 |
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | USA |
 |
Tandem Diabetes Care
TNDM
|
881 M | $ 21.64 | -7.2 % | $ 1.47 B | USA |
 |
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
39.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | USA |
 |
CONMED Corporation
CNMD
|
2.33 B | $ 35.8 | -2.29 % | $ 1.11 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
210 M | $ 2.21 | -2.64 % | $ 130 M |  Israel |
 |
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | Israel |
 |
NanoVibronix
NAOV
|
3.63 M | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
53.8 M | $ 24.35 | -0.41 % | $ 206 M | USA |
 |
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M |  Canada |
 |
Viemed Healthcare
VMD
|
199 M | $ 9.26 | 0.43 % | $ 360 M | USA |
 |
Varex Imaging Corporation
VREX
|
1.11 B | $ 10.78 | - | $ 446 M | USA |
 |
Outset Medical
OM
|
264 M | $ 3.39 | -3.69 % | $ 51.6 K | USA |
 |
Vivos Therapeutics
VVOS
|
15.3 M | $ 1.17 | -2.03 % | $ 5.87 M | USA |
 |
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
47.4 M | $ 0.61 | 0.82 % | $ 33.2 M | USA |
 |
Aethlon Medical
AEMD
|
7.36 M | $ 2.26 | -0.44 % | $ 3.53 M | USA |
 |
PAVmed
PAVM
|
33.1 M | $ 8.77 | -1.9 % | $ 63.4 M | USA |
 |
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | USA |
 |
InspireMD
NSPR
|
69.4 M | $ 1.67 | -3.47 % | $ 107 M | Israel |
 |
Beyond Air
XAIR
|
30.1 M | $ 0.67 | -2.84 % | $ 45.4 M | USA |
 |
AdaptHealth Corp.
AHCO
|
4.32 B | $ 11.25 | -1.4 % | $ 1.52 B | USA |
 |
Penumbra
PEN
|
1.83 B | $ 335.34 | -0.32 % | $ 13.1 B | USA |
 |
Zimmer Biomet Holdings
ZBH
|
21.4 B | $ 87.82 | -1.49 % | $ 17.8 B | USA |
 |
MiMedx Group
MDXG
|
343 M | $ 3.82 | -3.05 % | $ 565 M | USA |
 |
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | USA |
 |
Ra Medical Systems
RMED
|
16.8 M | - | 10.0 % | $ 610 K | USA |
 |
Myomo
MYO
|
38.6 M | $ 0.68 | -0.31 % | $ 28.5 M | USA |
 |
TELA Bio
TELA
|
81.4 M | $ 0.64 | -14.68 % | $ 30 M | USA |
 |
Inspire Medical Systems
INSP
|
907 M | $ 49.12 | -2.54 % | $ 1.44 B | USA |
 |
Pulmonx Corporation
LUNG
|
129 M | $ 1.2 | -3.33 % | $ 48.8 M | USA |
 |
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | USA |
 |
Eargo
EAR
|
132 M | - | - | $ 10.2 M | USA |